

**DESCRIPTIVE TABLE OF THE DELEGATIONS AND AUTHORIZATIONS TO BE SUBMITTED TO THE EXTRAORDINARY SHAREHOLDERS' MEETING  
OF MAY 23, 2024**

Dear Shareholders,

At the Annual General Meeting of May 12, 2023 ( **the " 2023 EGM "** ), you approved a number of financial delegations. Most of these delegations are for a period of 26 months, so it is not normally necessary to renew them at the Annual General Meeting of May 20, 2024 ( **the "2024 EGM "** ). However, a Draft law (n°2321) " *aimed at increasing the financing of companies and the attractiveness of France* " was presented to the National Assembly on March 12, 2024. This proposal contains provisions that would impact the drafting of these resolutions.

In order to be able to benefit from these new rules when they are adopted (if they are adopted), it is proposed to renew in advance, by modifying them, some of the resolutions adopted at the 2023 EGM, while giving them a shorter lifespan - 18 months - in order to find in 2025, as every two years, the complete renewal of all these financial delegations. Please refer to the Management Board's Report to the Annual General Meeting (Section II. 1) for further explanations on the potential changes arising from the proposed Draft law (n°2321) " *aimed at increasing the financing of companies and the attractiveness of France* ".

At the 2024 Extraordinary General Meeting, it will also be proposed to renew and add to the delegations and financial authorizations relating to equity instruments for corporate officers and employees of the Company and its subsidiaries.

The table below summarizes

- a reminder of the main points concerning the resolutions adopted at the 2023 EGM, which will remain in force and unchanged after the 2024 EGM;
- an explanation of the main points concerning each of the financial resolutions to be submitted to the 2024 EGM.

**Non-official translation – For information purpose only**

Resolution N°	SUBJECT MATTER OF THE RESOLUTION	DESCRIPTION
<b>I. Resolutions adopted at the 2023 EGM and still in force</b>		
22	Delegation of authority to the Executive Board for the purpose of issuing ordinary Company shares and/or of securities giving access to the share capital of the Company, with shareholders' preferential subscription rights ("Rights Issue")	<ul style="list-style-type: none"> <li>• Share capital increase with shareholders' preferential subscription rights : shareholders have a preferential subscription right to subscribe on an irreducible basis (in proportion to the rights they hold) and as the case may be, on a reducible basis.</li> <li>• Total nominal amount of share capital increases that can be decided under this resolution: €1,207,776.85.</li> <li>• Maximum number of shares that can be issued under this resolution: 24,155,537 shares.</li> <li>• Deduction of each share capital increase decided under this resolution from the overall capped amount of €1,207,776.85 (resolution n°31 of the EGM 2023).</li> <li>• Maximum nominal amount of debt securities giving access to share capital that can be issued under this resolution: €150,000,000.</li> <li>• The Executive board can limit the amount of share capital increase to at least <math>\frac{3}{4}</math> of the total decided amount, if the entire share capital increase is not subscribed.</li> <li>• The use of this delegation by the Executive board is subject to the prior approval of the Supervisory board.</li> <li>• Voids the 18<sup>th</sup> resolution of the Shareholders' Meeting of May 20, 2022.</li> <li>• Validity period: 26 months.</li> </ul>

**Non-official translation – For information purpose only**

Resolution N°	SUBJECT MATTER OF THE RESOLUTION	DESCRIPTION
27	<p><b>Delegation of authority to the Executive Board for the purpose of issuing ordinary shares of the Company, without shareholders' preferential subscription rights and reserved for certain categories of investors within the framework of an equity financing agreement on the United States stock market known as "AtThe-Market" or "ATM Program</b></p>	<ul style="list-style-type: none"> <li>• Possibility of carrying out a capital increase with cancellation of the preferential subscription right and of reserving the right to subscribe to : <ul style="list-style-type: none"> <li>- any French or foreign credit institution,</li> <li>- any French or foreign investment services provider, or</li> <li>- any foreign institution with an equivalent status,</li> </ul> Intervening within the framework of an ATM Program set up by the Company. </li> <li>• Total nominal amount of the capital increases that can be decided under this resolution: 1,207,776.85 euros.</li> <li>• Maximum number of shares that can be issued under this resolution: 24,155,537 shares.</li> <li>• Deduction of each capital share increase decided under this resolution from the overall cap amount of 1,207,776.85 euros (resolution n°31 of the EGM 2023).</li> <li>• Minimum issuing price : <ul style="list-style-type: none"> <li>- Volume-weighted average (in the central order book and excluding off-market blocks) of the Company's share price over the last five stock market trading days preceding the setting of the issue price</li> <li>- The last closing price of the Company's share preceding the setting of the issue price</li> </ul> In both cases: possible maximum discount of 15 </li> <li>• Maximum nominal amount of debt securities giving access to the capital that can be issued under this resolution</li> <li>• The use of this delegation by the Executive board is subject to the prior approval of the Supervisory board</li> <li>• Validity period: 18 months. Renewal of this resolution is not requested.</li> </ul>

**Non-official translation – For information purpose only**

Resolution N°	SUBJECT MATTER OF THE RESOLUTION	DESCRIPTION
28	<b>Authorization granted to the Executive board to increase of 15% the number of securities to be issued in the event of a share capital increase, with or without shareholders' preferential subscription rights</b>	<ul style="list-style-type: none"> <li>• Overallotment option: possibility to increase the number of securities to be issued at the same price: <ul style="list-style-type: none"> <li>- Within the 30 days following the closing of the subscription, and</li> <li>- Within the limit of 15% of the initial issuance and at the same initial issuance price</li> </ul> </li> <li>• Deduction of each share capital increase decided under this resolution from the capped amount of €1,207,776.85 (resolution n°31 of the EGM 2023)</li> <li>• Application to share capital increases with or without shareholders' preferential subscription rights (resolutions n°22 and 27 of the EGM 2023)</li> <li>• Validity period: 26 months</li> </ul>
30	<b>Delegation of authority to the Executive Board for the purpose of issuing ordinary shares and/or securities giving access to the share capital of the Company, in the event of a public exchange offer initiated by the Company</b>	<ul style="list-style-type: none"> <li>• Share capital increase carried out by way of a public exchange offer</li> <li>• Total nominal amount of share capital increases that can be decided under this resolution: €1,207,776.85</li> <li>• Maximum number of shares that can be issued under this resolution: 24,155,537 shares</li> <li>• Deduction of each share capital increase decided under this resolution from the overall capped amount of €1,207,776.85 (resolution n°31 of the EGM 2023)</li> <li>• The use of this delegation by the Executive board is subject to the prior approval of the Supervisory board</li> <li>• Voids the 25<sup>th</sup> resolution of the Shareholders' Meeting of May 20, 2022</li> <li>• Validity period: 26 months</li> </ul>
31	<b>Overall limitation on authorizations</b>	<ul style="list-style-type: none"> <li>• Overall capped amount of €1,207,776.85 applicable to resolutions n°22, 27, 28 and 30 of the 2023 EGM and resolutions 19 to 23 of the 2024 EGM ( see below).</li> </ul>

Resolution N°	SUBJECT MATTER OF THE RESOLUTION	DESCRIPTION
<b>II. Resolutions proposed at the 2024 EGM</b>		
19	<b>Delegation of authority to the Executive Board for the purpose of issuing ordinary Company shares and/or of securities giving access to the share capital of the Company, without shareholders' preferential subscription rights, through a public offering</b>	<ul style="list-style-type: none"> <li>• Share capital increase without shareholders' preferential subscription rights: shareholders do not have preferential subscription rights and all investors may subscribe. However, the Executive board may grant shareholders a priority right (exercised on an irreducible or reducible basis).</li> <li>• Total nominal amount of share capital increases that can be decided under this resolution: €1,207,776.85.</li> <li>• Maximum number of shares that can be issued under this resolution: 24,155,537 shares.</li> <li>• Deduction of each share capital increase decided under this resolution from the overall capped amount of €1,207,776.85 (resolution n°31 of the EGM 2023).</li> <li>• Minimum issuing price: (i) the minimum value set by the laws and regulations applicable at the time the delegation is used, i.e. currently the weighted average of the prices quoted over the last 3 trading sessions prior to the start of the public offering (with a possible maximum discount of 10%) or (ii) in the absence of a minimum price set by the laws and regulations applicable on the issue date, the weighted average of the prices quoted for the shares over the 5 trading days preceding the start of the public offering (with a possible maximum discount of 15%). The latter option having been added to enable the Company to benefit from the abolition of the minimum price concept, which is currently envisaged by the aforementioned Draft law.</li> <li>• Maximum nominal amount of debt securities giving access to share capital that can be issued under this resolution: €150,000,000. The possibility to increase the size of the transaction by 15%, within this maximum nominal amount, is included in the text of this resolution.</li> <li>• The use of this delegation by the Executive board is subject to the prior approval of the Supervisory board.</li> <li>• Voids the resolution n°23 of the 2023 EGM.</li> <li>• Validity period: 18 months.</li> </ul>

**Non-official translation – For information purpose only**

Resolution N°	SUBJECT MATTER OF THE RESOLUTION	DESCRIPTION
20	<p><b>Delegation of authority to the Executive Board for the purpose of issuing, without shareholder's preferential subscription rights, ordinary shares of the Company and/or securities giving access to the share capital of the Company, within the framework of an offering of private placement as described in paragraph 1° of Article L.411-2 of the French Monetary and Financial Code</b></p>	<ul style="list-style-type: none"> <li>• Possibility to carry out a share capital increase without shareholders' preferential subscription rights by way of a private placement reserved for the benefit of qualified investors or restricted to a limited circle of investors pursuant to paragraph 1° of Article L. 411-2 of the French Monetary and Financial Code</li> <li>• Total nominal amount of share capital increases that can be decided under this resolution: €1,207,776.85</li> <li>• Maximum number of shares that can be issued under this resolution: 24,155,537 shares</li> <li>• Deduction of each share capital increase decided under this resolution from the overall capped amount of €1,207,776.85 (resolution n°31 of the EGM 2023)</li> <li>• Minimum issuing price: (i) the minimum value set by the laws and regulations applicable at the time the delegation is used, i.e. currently the weighted average of the prices quoted over the last 3 trading sessions prior to the start of the public offering (with a possible maximum discount of 10%) or (ii) in the absence of a minimum price set by the laws and regulations applicable on the issue date, the weighted average of the prices quoted for the shares over the 5 trading days preceding the start of the public offering (with a possible maximum discount of 15%). The latter option having been added to enable the Company to benefit from the abolition of the minimum price concept, which is currently envisaged by the aforementioned Draft law.</li> <li>• Maximum nominal amount of debt securities giving access to share capital that can be issued under this resolution: €150,000,000. The possibility to increase the size of the transaction by 15%, within this maximum nominal amount, is included in the text of this resolution.</li> <li>• The use of this delegation by the Executive board is subject to the prior approval of the Supervisory board</li> <li>• Voids the 24<sup>th</sup> resolution of the 2023 EGM</li> <li>• Validity period: 18 months</li> </ul>

**Non-official translation – For information purpose only**

Resolution N°	SUBJECT MATTER OF THE RESOLUTION	DESCRIPTION
21	<b>Determination of the issuance price of the ordinary shares and/or of securities giving access to the share capital of the Company, in the event of the suppression of shareholders' preferential subscription rights</b>	<ul style="list-style-type: none"><li>• Possibility to carry out a share capital increase without shareholders' preferential subscription rights coupled with a minimum price formula different from the legal price formula: price at least equal to the volume-weighted average of the prices of the Company's share on Euronext during the last 5 stock market trading days preceding the date upon which the issuance price is set with a maximum discount of 15%</li><li>• Limitation in accordance with the legal provisions in force on the issue date, i.e. currently 10% of the capital per year.</li><li>• Application to capital increases without shareholders' preferential subscription rights (resolutions 19 and 20 of the 2024 EGM).</li><li>• Validity period: 18 months</li></ul>

**Non-official translation – For information purpose only**

Resolution N°	SUBJECT MATTER OF THE RESOLUTION	DESCRIPTION
22	<p><b>Delegation of authority to the Executive Board for the purpose of issuing of ordinary Company shares and /or of securities giving access to the share capital of the Company, without shareholders' preferential subscription rights and reserved for certain categories of investors</b></p>	<ul style="list-style-type: none"> <li>• Possibility to carry out a share capital increase without shareholders' preferential subscription rights and to reserve the right to subscribe:</li> <li>(a) as part of an industrial or strategic agreement with the Company, to: <ul style="list-style-type: none"> <li>— industrial or commercial companies involved in the pharmaceutical / biotechnological sector, or</li> <li>— investment companies or investment funds' management companies or to investment funds, governed by French or foreign law, or</li> <li>— any other legal person (including a trust) or natural person that invests on a regular basis, in the pharmaceutical / biotechnological sector, and</li> </ul> </li> <li>(b) in the context of an offer pursuant to article L.411-2 1° of the French Monetary and Financial Code for French investors and pursuant to the equivalent provisions for foreign investors to: <ul style="list-style-type: none"> <li>— industrial or commercial companies involved in the pharmaceutical / biotechnological sector, or</li> <li>— investment companies or investment funds' management companies or to investment funds, governed by French or foreign law, usually investing in the pharmaceutical/biotechnological sector, or</li> <li>— any other legal person (including a trust) or natural person that invests on a regular basis, in the pharmaceutical / biotechnological sector,</li> </ul> </li> <li>meeting, in each of the cases referred to above, the criteria for participating in such an offer, or</li> <li>— investment services providers, governed by French or foreign law, able to underwrite the completion of such an offer;</li> <li>(c) as part of a debt-financing transaction with credit institutions or other institutions granting this type of financing to the lenders in question.</li> <li>• Total nominal amount of share capital increases that can be decided under this resolution: €1,207,776.85</li> <li>• Maximum number of shares that can be issued under this resolution: 24,155,537 shares</li> <li>• Deduction of each share capital increase decided under this resolution from the overall capped amount of €1,207,776.85 (resolution n°31)</li> <li>• Minimum issuing price: weighted average of share price for the last 5 stock market trading days preceding the date on which the issuance price is set with a maximum discount of 15%</li> <li>• Maximum nominal amount of debt securities giving access to share capital that can be issued under this resolution: €150,000,000. The possibility to increase the size of the transaction by 15%, within this maximum nominal amount, is included in the text of this resolution.</li> <li>• The use of this delegation by the Executive board is subject to the prior approval of the Supervisory board</li> <li>• Voids the 26<sup>nd</sup> resolution of the 2023 EGM</li> <li>• Validity period: 18 months</li> </ul>



**Non-official translation – For information purpose only**

Resolution N°	SUBJECT MATTER OF THE RESOLUTION	DESCRIPTION
23	<b>Delegation of authority to the Executive Board for the purpose of issuing ordinary shares and/or securities giving access to the share capital of the Company, as compensation for contributions in kind comprised of equity securities or securities giving access to the share capital</b>	<ul style="list-style-type: none"> <li>• Possibility to carry out share capital increase to remunerate contributions in kind comprised of equity securities or securities giving access to the share capital</li> <li>• Limitation in accordance with the legal provisions in force on the issue date, i.e. currently 10% of the capital per year.</li> <li>• Maximum nominal amount of debt securities giving access to share capital that can be issued under this resolution: €150,000,000</li> <li>• Deduction of each share capital increase decided under this resolution from the capped amount of €1,207,776.85 (resolution n°31 of the EGM 2023)</li> <li>• The use of this delegation by the Executive board is subject to the prior approval of the Supervisory board</li> <li>• Voids the 29<sup>th</sup> resolution of 2023 EGM.</li> <li>• Validity period: 18 months</li> </ul>
24	<b>Authorization granted to the Executive Board to allocate stock options for the benefit of employees, executive officers, employed members of the Executive Committee, employed senior executives and/or corporate officers of the Company or its subsidiaries.</b>	<ul style="list-style-type: none"> <li>• Share subscription and/or purchase options for the benefit of employees, executive officers, employed members of the Executive Committee, employed senior executives and/or corporate officers of the Company or its subsidiaries</li> <li>• Total nominal amount of the capital increase that may be decided pursuant to this resolution: €7,500.</li> <li>• Maximum number of shares that may be issued under this authorization: 150,000 ordinary shares.</li> <li>• Use of this authorization by the Executive Board subject to the prior authorization of the Supervisory Board.</li> <li>• Duration of the authorization: 38 months.</li> </ul>

**Non-official translation – For information purpose only**

Resolution N°	SUBJECT MATTER OF THE RESOLUTION	DESCRIPTION
25 and 26	<p><b>Authorization granted to the Executive Board to allocate existing or new free shares on the basis of the performance criteria for the benefit of executive officers, employed members of the Executive Committee, employed senior executives and/or corporate officers and employees of the Company or its subsidiaries</b></p>	<ul style="list-style-type: none"> <li>Free allocation of performance shares (the “<b>Performance Free Shares</b>”) for the benefit of (i) employed members of the Executive Committee, employed senior executives and/or corporate officers (resolution n°25) and (ii) employees (resolution n°26) of the Company and its consolidated subsidiaries under Article L. 225-197-1 et seq. of the French Commercial code (list or relevant beneficiaries established by the Executive board)</li> <li>Total nominal amount of share capital increases that can be decided under this resolution resulting from the allocation and definitive acquisition of all the Performance Free Shares: <ul style="list-style-type: none"> <li>(i) for the benefit of employed members of the Executive Committee, employed senior executives and/or corporate officers (resolution n°25): €71,250</li> <li>(ii) for the benefit of employees (resolution n°26): €60,000</li> </ul> </li> <li>Maximum number of shares that can be issued under these resolutions: <ul style="list-style-type: none"> <li>(i) for the benefit of employed members of the Executive Committee, employed senior executives and/or corporate officers (resolution n°25): 1 425,000</li> <li>(ii) for the benefit of employees (resolution n°26): 1,200,000</li> </ul> <p>The maximum number of Free Performance Shares that may be definitely acquired shall depend on the achievement of performance criteria as defined by the Supervisory board, upon recommendation of the Compensation and nomination committee.</p> </li> <li>Acquisition period: maximum three years as from the allocation, subject to presence condition</li> <li>No lock-up period</li> <li>The use of this delegation by the Executive board requires the prior approval of the Supervisory board</li> <li>Voids the authorizations granted by the 32<sup>th</sup> and 33rd resolution of 2023 EGM</li> <li>Validity period: 38 months</li> </ul>

**Non-official translation – For information purpose only**

Resolution N°	SUBJECT MATTER OF THE RESOLUTION	DESCRIPTION
27	<b>Authorization granted to the Executive Board to allocate existing or new free shares for the benefit of executive officers, employed members of the Executive Committee, employed senior executives and/or corporate officers of the Company or its subsidiaries</b>	<ul style="list-style-type: none"> <li>• Allocation of free shares to executive officers, employed members of the Executive Committee, employed senior executives and/or corporate officers of the Company or its subsidiaries</li> <li>• Total nominal amount of the capital increase that can be decided under this resolution: 15,000 euros.</li> <li>• Maximum number of shares that can be issued under this resolution: 300,000 ordinary shares.</li> <li>• Acquisition period: maximum three years as from the allocation, subject to presence condition</li> <li>• The use of this delegation by the Executive board requires the prior approval of the Supervisory board</li> <li>• Validity period: 38 months</li> </ul>
28	<b>Delegation of authority to the Executive Board for the purpose of issuing ordinary shares and/or securities giving access to the share capital of the Company for the benefit of the members of a company savings plan (CSP)</b>	<ul style="list-style-type: none"> <li>• Share capital increase reserved for the benefit of employed members of a CSP</li> <li>• Total nominal amount of share capital increases that can be decided under this resolution: €15,000</li> <li>• Maximum number of shares that can be issued under this resolution: 300,000 shares</li> <li>• Minimum issuance price: <ul style="list-style-type: none"> <li>- when the duration of the lock-up period stipulated by the savings plan is less than 10 years: 80% of the average of the first listed prices of the Company's share on the Euronext Paris stock exchange during the twenty stock market trading days preceding the date of the decision setting the opening date for subscription</li> <li>- when said lock-up period is greater than or equal to 10 years: to 70% of the average of the first listed prices of the Company's share on the Euronext Paris stock exchange during the twenty stock market trading days preceding the date of the decision setting the opening date for subscription</li> </ul> </li> <li>• The use of this delegation by the Executive board requires the prior approval of the Supervisory board</li> <li>• Voids the resolution n°35 of the 2023 EGM</li> <li>• Validity period: 26 months</li> </ul>

**Non-official translation – For information purpose only**

Resolution N°	SUBJECT MATTER OF THE RESOLUTION	DESCRIPTION
29	<b>Delegation of authority to the Executive Board for the purpose of issuing autonomous share subscription warrants reserved for Supervisory Board members</b>	<ul style="list-style-type: none"> <li>• Issue of warrants to members of the Supervisory Board (list of members concerned determined by the Executive Board).</li> <li>• Total nominal amount of share capital increases that can be decided under this resolution: €2,000.</li> <li>• Maximum number of shares that can be issued under this resolution: 40 000 shares.</li> <li>• Exercise price at least equal to the average of the closing prices of the last ten trading days at the time of allocation of the warrants</li> <li>• Subscription price of the warrants equal to the market value of the warrants, determined at the date of their allocation by the Executive Board, by an independent expert appointed by the Executive Board.</li> <li>• The use of this delegation by the Executive board requires the prior approval of the Supervisory board</li> <li>• Voids the resolution n°36 of the 2023 EGM</li> <li>• Validity period: 18 months</li> </ul>
30	<b>Delegation of power to the Executive board for the purpose of cancelling all or part of the treasury share of the Company, acquired pursuant to the authorization to repurchase shares</b>	<ul style="list-style-type: none"> <li>• Limit in accordance with the legal provisions in force on the issue date: i.e; currently 10% of the share capital per 24-month period.</li> <li>• Voids the resolution n°37 of the 2023 EGM</li> <li>• Validity period : 18 months</li> </ul>